News | Atrial Fibrillation | April 01, 2022

Cardiologs Announces Poster Presentation at ACC 2022

New clinical data shows Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm 

The poster titled “Short term prediction of Atrial Fibrillation from ambulatory ECG using deep learning” presents results of a clinical study demonstrating that Cardiologs’ AI algorithm can predict the short-term risk of atrial fibrillation (AFib) based on single-lead Ambulatory electrocardiograms (ECGs) that show normal sinus rhythm.

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in Washington, DC, from April 2-4, 2022. 

The poster titled “Short term prediction of Atrial Fibrillation from ambulatory ECG using deep learning” presents results of a clinical study demonstrating that Cardiologs’ AI algorithm can predict the short-term risk of atrial fibrillation (AFib) based on single-lead Ambulatory electrocardiograms (ECGs) that show normal sinus rhythm. 

Previous studies have assessed the long-term possibility for future AFib using AI-based prediction algorithms based on normal 12-lead ECGs. This study shows Cardiologs’ deep neural network can reliably predict whether Afib will occur in the near future (i.e., within 6 to 14 days) with an area under the curve of 0.79, a ten-point improvement over a basic age and sex-based model. 

"In most countries, the short-term Holter is the first ambulatory arrhythmia diagnostic test and, too often, the last. By bringing predictive AFib capabilities to the Holter test, we empower cardiologists to pursue the search for AFib without changing the care pathway. Cardiologs’ AI can predict the presence of AFib, even when there are no visible signs in the ECG recordings. The algorithm can detect subtle symptoms that suggest future onset, giving much more value to the Holter and helping physicians determine which patients may benefit from long-term monitoring." said Cardiologs CEO and Co-Founder Yann Fleureau.  

AFib remains the most common sustained cardiac arrhythmia, affecting 46 million individuals worldwide. Identifying patients with AFib is a growing priority given the high association with stroke and heart failure, but symptoms often come and go – making the condition challenging to catch. Though convenient, short Holter recordings (24-48 hours) commonly used to confirm suspected AFib have a low detection rate and cannot predict future occurrences. 

For more information: www.cardiologs.com 

Find more ACC22 content here


Related Content

News | ACC

June 1, 2023 — The American College of Cardiology will host the annual Care of the Athletic Heart course on June 8-10 ...

Home June 01, 2023
Home
News | ACC

May 26, 2023 — The Clinical Hospital of Emergency Services, a municipal hospital serving the community of Dnipro, in ...

Home May 26, 2023
Home
News | ACC

April 11, 2023 — A newly-published study in the Journal of the American College of Cardiology, JACC, the flagship ...

Home April 11, 2023
Home
News | ACC

March 21, 2023 — As part of its extensive coverage, the editorial team at dicardiology.com/DAIC has shared summary ...

Home March 21, 2023
Home
News | ACC

March 16, 2023 — The American College of Cardiology (ACC) announced the winners and finalists of its 2023 Young ...

Home March 16, 2023
Home
News | ACC

March 12, 2023 — As part of its ongoing news coverage of ACC23, the DAIC/dicardiology.com editorial team has condensed ...

Home March 12, 2023
Home
News | ACC

March 9, 2023 — C. Noel Bairey Merz, MD, FACC, professor of cardiology and the director of the Barbra Streisand Women’s ...

Home March 09, 2023
Home
News | ACC

March 9, 2023 — Positive results from a Mineralys Therapeutics study, the Target-HTN Phase 2 trial, demonstrated ...

Home March 09, 2023
Home
News | ACC

March 8, 2023 — B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology. Today marks the ...

Home March 08, 2023
Home
News | ACC

March 6, 2023 — In findings presented from the STELLAR Phase III Trial during the American College of Cardiology’s 2023 ...

Home March 06, 2023
Home
Subscribe Now